Clusterin Human ELISA

Summary

Clusterin (Apolippoprotein J; SP-40,40; TRPM-2; SGP-2; pADHC-9; CLJ; T64; GP III; XIP8) is a highly conserved disulfide-linked secreted heterodimeric glycoprotein of 75–80 kDa but truncated forms targeted to the nucleus have also been identified. The protein is constitutively secreted by a number of cell types including epithelial and neuronal cells and is a major protein in physiological fluids including plasma, milk, urine, cerebrospinal fluid and semen. Due to its wide breath of tissue distribution many diverse physiological functions have been attributed to Clusterin including sperm maturation, membrane recycling, lipid transportation, tissue remodelling, complement inhibition and cell-cell or cell-substratum interactions. Moreover, it was proposed that Clusterin functions as an extracellular chaperon that stabilizes stressed proteins in a folding-competent state, and that the protein is involved in programmed cell death. Another defining prominent function of Clusterin is its induction in many severe physiological disturbances states including kidney degenerative diseases, prostate and vesicle carcinogenesis, ovarian cancer and several neurodegenerative conditions (Alzheimer’s di­sease). Recent study demonstrates, that serum Clusterin level increases significantly in diabetic type II patients and in patients with developing coronary heart disease, or myocardial infarction. These data raise the possibility that elevated Clusterin levels in serum may represent a strong indication of vascular damage. In patients with systemic lupus erythematosus (SLE), reduced serum Clusterin levels correlated inversely with disease activity. Lowered Clusterin levels could be involved in the pathogeneses of SLE on account of decreased protective effects. Another interesting observation obtained in rat model suggests that measurement of urinary Clusterin levels may be a useful clinical marker for the severity of renal tubular damage. Furthermore, urinary Clusterin may also help to differentiate between tubular and glomerular forms of proteinuria.

Areas of investigation: Coronary heart diseases, Myocardial infarction, Neurodegenerative diseases, Kidney degenerative disease, Renal tubular damage

Features

• It is intended for research use only.
• The total assay time is less than 3.5 hours.
• The kit measures Clusterin in serum, plasma, cerebrospinal fluid (CSF), urine, cell culture, and cell lysate.
• Components of the kit are provided ready to use, concentrated or lyophilized.
• Standard is recombinant protein based.
• Quality Controls are human serum based. No animal sera are used.

Research topic

Others, Renal disease, Sepsis

Find out more on biovendor.com

• Does the Enigmatic Clusterin Have a Chaperone-Like Activity During Sepsis in Children? in BioVendor News
• Clusterin in BioVendor Reviews

Assay format

Sandwich ELISA, Biotin-labelled antibody

Applications

Cell lysate, Cerebrospinal fluid, Plasma-Citrate, Plasma-EDTA, Plasma-Heparin, Serum, Urine

Sample requirements

5 µl/well

Storage/Shipping

2–8°C

Calibration Curve

Calibration range

5 – 160 ng/ml

Limit of detection

0.5 ng/ml

Intra-assay (Within-Run, n=8)

CV = 6.2 %

Inter-assay (Run-to-Run, n=8)

CV = 7.8 %

Spiking Recovery

102.8 %

Dilution Linearity

98.3 %

Cross-Reactivity

References to this product

• Aguilar-Mahecha A, Cantin C, O'Connor-McCourt M, Nantel A, Basik M. Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker. Proteome Sci. 2009;7:15
• Banfi C, Parolari A, Brioschi M, Barcella S, Loardi C, Centenaro C, Alamanni F, Mussoni L, Tremoli E. Proteomic analysis of plasma from patients undergoing coronary artery bypass grafting reveals a protease/antiprotease imbalance in favor of the serpin alpha1-antichymotrypsin. J Proteome Res. 2010 May 7;9 (5):2347-57
• Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Sep 20;28 (27):4247-54
• Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res. 2009 Jan 15;15 (2):708-13
• Cubedo J, Padro T, Garcia-Moll X, Pinto X, Cinca J, Badimon L. Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res. 2011 Jan 7;10 (1):211-20
• Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007 Jul;6 (7):2833-40
• Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology. 2010 Feb;75 (2):454-9
• Rithidech KN, Honikel L, Milazzo M, Madigan D, Troxell R, Krupp LB. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult Scler. 2009 Apr;15 (4):455-64
• Schlatzer D, Maahs DM, Chance MR, Dazard JE, Li X, Hazlett F, Rewers M, Snell-Bergeon JK. Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care. 2012 Mar;35 (3):549-55
• Seferovic MD, Chen S, Pinto DM, Gupta MB. Altered liver secretion of vascular regulatory proteins in hypoxic pregnancies stimulate angiogenesis <i>in vitro</i>. J Proteome Res. 2011 Feb 15;
• Solichova P, Karpisek M, Ochmanova R, Hanulova Z, Humenanska V, Stejskal D, Bartek J. Urinary clusterin concentrations--a possible marker of nephropathy? Pilot study. Biomed Pap Med Fac Univ Palack. 2007 Dec;151 (2):233-6
• Stejskal D, Fiala RR. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma . 53(4):343-6 (2006)
• Stejskal D, Lacnak B, Karpisek M, Kaminek M. Our experiences with measurement of new potential biomarkers in the diagnosis of latent forms of myocardial ischemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub . Dec;150(2):239-44 (2006)
• Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010 Jul;67 (7):739-48
• Vareka I, Stejskal D, Varekova R, Burianova K, Hnatek J. Changes in clusterin serum concentration levels in oncologic patients during the course of Spa therapy – a pilot study. Biomed Pap Med Fac Univ Palack. 2009; 153:117-120;
• Wang Y, Liu YH, Mai SJ, He LJ, Liao YJ, Deng HX, Guan XY, Zeng YX, Kung HF, Xie D. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis . Journal of Gastroenterology an. 25 (2010) 1123–1128;
• Zhang F, Sha J, Wood TG, Galindo CL, Garner HR, Burkart MF, Suarez G, Sierra JC, Agar SL, Peterson JW, Chopra AK. Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA). Cell Signal. 2008 May;20 (5):844-61
• Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW, Chopra AK. Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell Signal. 2009 Jul;21 (7):1085-99

References to summary

• Choi-Miura NH, Oda T: Relationship between multifunctional protein Clusterin and Alzheimer disease. Neurobiol. Aging 1996; 17(5): 717–722
• Newkirk MM, Apostolakos P, Neville C and Fortin PR: Systemic lupus erythematosus, a disease associated with low levels of Clusterin/ApoJ, and anti-inflammatory protein. J. Rheumatol.1999; 3:597–603
• Morrissey C, Lakins J, Moquin A, Hussain M, Tenniswood M: An antigen capture assay for the measurement of serum Clusterin concentrations. J. Biochen. Biophys. Methods 2001; 48:13–21
• Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES: Serum levels of the senescence biomarker Clusterin/apo­lipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Ex. Gerontology 2002; 37: 1175–1187
• Jones SE, Jomary C: Molecules in focus Clusterin. The International J. of Bioch. & Cell Biol. 2002; 34:427–431
• Hidaka S, Kränzlin B, Gretz N, Witzgall R: Urinary Clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res. 2002; 310:289–296
• Chen X, Halberg RB, Ehrhardt WM, Torrealba J and Dove WF: Clusterin as a biomarker in murine and human intestinal neoplasia. PNAS 2003; 100:9530–9535
• Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y, Wu M, Qian XH and Zhao XH: Loss of Clusterin both in serum and tissue correlates with the tumorogenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003; 9:650–654
• Wang L, Erling P, Bengtsson AA, Truedsson L, Sturfelt G, Erlinge D: Transcriptional down-regulation of the platelet ADP receptory P2Y12 and Clusterin in patients with systemic lupus erythematosus. J. of Thromb. And Haemost. 2004; 2:1436–1442
• Patel NV, Wei M, Wong A, Finch CE, Morgan TE: Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neuroscience Letters 2004; 371:199–204
• Kim BM, Kim SY, Lee S, Shin YJ, Min BH, Bendayan M, Park IS: Clusterin induces differentiation of pancreatic duct calls into insulin-secreting cells. Diabetologia 2006; 49:311–320
• Kruger S, Mahnken A, Kausch I, Feller AC: Value of Clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006; 67:105–109
• Stejskal D, Fiala R: Evaluation of serum and urine Clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 2006; 53:343–34

By research topic:

• Others
• Renal disease
• Sepsis

By molecule:

• Clusterin

Registration form